12 Health Care Stocks Moving In Friday's Intraday Session
I'm LongbridgeAI, I can summarize articles.During Friday's intraday session, several healthcare stocks experienced significant volatility. Gainers included EUDA Health Holdings (+22.3%), Forte Biosciences (+18.39%), and WORK Medical Tech (+15.84%). Conversely, notable losers were Virax Biolabs Group (-33.0%), Catheter Precision (-29.23%), and SILO Pharma (-26.78%). The report highlights specific price movements and market capitalizations for these listed companies.
Gainers
- EUDA Health Holdings (NASDAQ:EUDA) shares rose 22.3% to $15.2 during Friday's regular session.
- Forte Biosciences (NASDAQ:FBRX) shares moved upwards by 18.39% to $43.45. The market value of their outstanding shares is at $751.5 million.
- WORK Medical Tech Gr (NASDAQ:WOK) shares increased by 15.84% to $2.34. The market value of their outstanding shares is at $4.8 million.
- NuCana (NASDAQ:NCNA) shares increased by 14.52% to $1.42. The company's market cap stands at $5.1 million.
- Jasper Therapeutics (NASDAQ:JSPR) shares rose 12.64% to $0.65. The company's market cap stands at $16.2 million.
- Rapid Micro Biosystems (NASDAQ:RPID) shares rose 10.91% to $1.93. The market value of their outstanding shares is at $86.6 million.
Losers
- Virax Biolabs Group (NASDAQ:VRAX) stock declined by 33.0% to $4.26 during Friday's regular session. The company's market cap stands at $5.0 million.
- Catheter Precision (AMEX:VTAK) stock declined by 29.23% to $0.81. The company's market cap stands at $4.1 million.
- SILO Pharma (NASDAQ:SILO) stock decreased by 26.78% to $5.66. The company's market cap stands at $8.3 million.
- BiomX (AMEX:PHGE) stock decreased by 20.17% to $0.22. The market value of their outstanding shares is at $3.3 million.
- Profusa (NASDAQ:PFSA) shares declined by 16.54% to $2.12. The company's market cap stands at $1.3 million.
- SciSparc (NASDAQ:SPRC) stock fell 15.42% to $4.61. The company's market cap stands at $3.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.